Breaking News

WuXi Biologics Co. Removed from U.S. Unverified List

CRDMO's subsidiary located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce effective October 7, 2022.

WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022.
 
In February 2022, two subsidiaries of WuXi Biologics, WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd., were placed on the UVL due to delayed verifications required for the receipt of certain products exported from the United States. In June, WuXi Biologics Co., Ltd. successfully completed the on-site end-use check conducted by the U.S. Department of Commerce, in coordination with China’s Ministry of Commerce (MOFCOM).
 
The company is also working closely with relevant government authorities to schedule the on-site end-use check of its other subsidiary, WuXi Biologics (Shanghai) Co., Ltd., and will commence the UVL delisting process for such entity as soon as the check is completed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters